BioSpace News Archive

Ongoing zuranolone Phase 3 pivotal trials in major depression and postpartum depression progressing well; expect to initiate dosing in CORAL Study in 4Q 2020

Patients Treated with LYNPARZA and Bevacizumab Lived Without Disease Progression or Death for a Median of 37.2 Months vs. 17.7 Months for Bevacizumab Alone Following Response to Platinum-Based Chemotherapy

Only PARP Inhibitor to Demonstrate Overall Survival Versus New Hormonal Agent Treatments in BRCA1/2-Mutated mCRPC

- Third quarter 2020 net revenues of $53.0 million; net income of $0.4 million and diluted eps of $0.04 - - Third quarter adjusted non-GAAP EBITDA of $17.0 million and adjusted non-GAAP diluted eps of $0.97 - - Cortrophin ® Gel sNDA re-filing on track; commercialization and operational launch readiness plan underway - - New CEO and Board members add breadth of experience and strengthen capabilities to drive business growth -

Eight abstracts accepted for presentation emphasize the potential of targeted C3 therapy to elevate the standard of care in paroxysmal nocturnal hemoglobinuria (PNH)

Operating margin up year-over-year on GAAP and adjusted basis Revenue improved sequentially with solid CRO/pharma demand and academic labs reopening Generated positive operating cash flow in Q3 with working capital improvements

Preliminary results from first patient in ongoing proof-of-concept trial show evidence of engraftment of gene-modified cells three months following treatment

Third Quarter2020 RevenueIncreases17% Year-Over-Year to $40.0 Million

Plus Therapeutics, Inc., a clinical-stage company focused on making a positive impact on patients’ lives, announced the formation of a Scientific Advisory Board with the appointment of leading experts in the fields of neuro-oncology, preclinical drug development, and nanotechnology.

BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Thursday, November 12, 2020 at 8:30 AM Eastern Time to discuss its third quarter 2020 operating and financial results. Conference Call & Webcast Details Date/Time: T